×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CARA – cara therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CARA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
03:01 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/5
02:13 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/28
02:03 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/20
02:06 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/12
02:02 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/4
02:09 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/26
02:08 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/18
02:36 am
cara
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cara Therapeutics, Inc. (NASDAQ: CARA) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:12 pm
cara
Form 10-Q Cara Therapeutics, Inc. For: Sep 30
Low
Report
Form 10-Q Cara Therapeutics, Inc. For: Sep 30
11/6
04:51 pm
cara
Form 4 Cara Therapeutics, Inc. For: Nov 04 Filed by: Posner Christopher
Medium
Report
Form 4 Cara Therapeutics, Inc. For: Nov 04 Filed by: Posner Christopher
10/30
04:22 pm
cara
Form SC 13D Cara Therapeutics, Inc. Filed by: Vifor (International) Ltd
Medium
Report
Form SC 13D Cara Therapeutics, Inc. Filed by: Vifor (International) Ltd
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/29
Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
19.4%
7/23 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 13.2%
8/8 Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.2%
1/14 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.0%
3/13 Cara Therapeutics Inc (NASDAQ: CARA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.8%
7/12 Form 8-K Cara Therapeutics, Inc. For: Jul 08 4.7%
7/29 Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares 4.3%
6/29 Where Will Cara Therapeutics Be in 5 Years? [The Motley Fool] 4.0%
2/14 Form SC 13G/A Cara Therapeutics, Inc. Filed by: STATE STREET CORP 4.0%
12/10 Cara Therapeutics Inc (NASDAQ: CARA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.8%
7/23 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 13.2%
8/8 Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.2%
1/14 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.0%
3/13 Cara Therapeutics Inc (NASDAQ: CARA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.8%
7/12 Form 8-K Cara Therapeutics, Inc. For: Jul 08 4.7%
7/29 Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares 4.3%
6/29 Where Will Cara Therapeutics Be in 5 Years? [The Motley Fool] 4.0%
2/14 Form SC 13G/A Cara Therapeutics, Inc. Filed by: STATE STREET CORP 4.0%
12/10 Cara Therapeutics Inc (NASDAQ: CARA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.8%
TOP News Decliners
12/3
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
-34.0%
3/17 Form SEC STAFF LETTER Cara Therapeutics, Inc. -18.8%
4/21 Form 8-K Cara Therapeutics, Inc. For: Apr 21 -13.6%
3/27 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -13.2%
3/6 Form 4 Cara Therapeutics, Inc. For: Mar 04 Filed by: Ives Jeffrey L. -12.3%
7/24 Cara Therapeutics Announces Proposed Offering of Common Stock -11.4%
4/29 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -6.8%
11/5 Form 4 Cara Therapeutics, Inc. For: Nov 01 Filed by: Ives Jeffrey L. -6.4%
12/4 Form 4 Cara Therapeutics, Inc. For: Dec 02 Filed by: CHALMERS DEREK T -5.9%
7/17 Form 4 Cara Therapeutics, Inc. For: Jul 15 Filed by: Mohindru Mani -5.8%
3/17 Form SEC STAFF LETTER Cara Therapeutics, Inc. -18.8%
4/21 Form 8-K Cara Therapeutics, Inc. For: Apr 21 -13.6%
3/27 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -13.2%
3/6 Form 4 Cara Therapeutics, Inc. For: Mar 04 Filed by: Ives Jeffrey L. -12.3%
7/24 Cara Therapeutics Announces Proposed Offering of Common Stock -11.4%
4/29 Cara Therapeutics Inc (NASDAQ: CARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -6.8%
11/5 Form 4 Cara Therapeutics, Inc. For: Nov 01 Filed by: Ives Jeffrey L. -6.4%
12/4 Form 4 Cara Therapeutics, Inc. For: Dec 02 Filed by: CHALMERS DEREK T -5.9%
7/17 Form 4 Cara Therapeutics, Inc. For: Jul 15 Filed by: Mohindru Mani -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: